Lactate in cystic fibrosis sputum

Journal of Cystic Fibrosis

Volumn 10, Issue 1, 2011, Pages 37-44

  Bensel, Tobias ^a   Stotz, Martin ^a   Borneff Lipp, Marianne ^a   Wollschläger, Bettina ^a   Wienke, Andreas ^b   Taccetti, Giovanni ^c   Campana, Silvia ^c   Meyer, Keith C ^d   Jensen, Peter O ^e   Lechner, Ute ^b   Ulrich, Martina ^f   Döring, Gerd ^f   Worlitzsch, Dieter ^a,f  

^a MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e Rigshospitalet   (Denmark)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Cystic fibrosis; Exacerbations; Neutrophil granulocytes

Indexed keywords

ANTIBIOTIC AGENT; LACTIC ACID;

ADULT; AEROBIC METABOLISM; ANAEROBIC METABOLISM; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM; BIOSYNTHESIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG RESPONSE; FEMALE; GAS CHROMATOGRAPHY; HUMAN; LUNG FUNCTION; MALE; NEUTROPHIL; PNEUMONIA; SPECTROPHOTOMETRY; SPIROMETRY; SPUTUM LEVEL;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIA; CHILD; CHROMATOGRAPHY, GAS; COMPARATIVE EFFECTIVENESS RESEARCH; CYSTIC FIBROSIS; DRUG MONITORING; FEMALE; HUMANS; LACTIC ACID; MALE; MIDDLE AGED; NEUTROPHILS; PNEUMONIA; RESPIRATORY FUNCTION TESTS; SPECTROPHOTOMETRY; SPUTUM; TREATMENT OUTCOME;

EID: 78651425189     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2010.09.004     Document Type: Article

References (37)

1. Gibson R.L., Burns J.L., Ramsey B.W. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003, 168:918-951.
2. Ratjen F., Döring G. Cyst Fibros Lancet 2003, 361:681-689.
3. Riordan J.R., Rommens J.M., Kerem B.S., et al. Identification of the cystic fibrosis gene: cloning and characterization of the complementary DNA. Science 1989, 245:1066-1073.
4. Rommens J.M., Iannuzzi M.C., Kerem B.S., et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989, 245:1059-1065.
5. Kerem B.-S., Rommens J.M., Buchannan J.A., et al. Identification of the cystic fibrosis gene: genetic analysis. Science 1989, 245:1073-1080.
6. Döring G., Hoiby N. Early intervention and prevention of lung disease in cystic fibrosis: a European consensus. J Cyst Fibros 2004, 3:67-91.
7. Chmiel J.F., Berger M., Konstan M.W. The role of inflammation in the pathophysiology of CF lung disease. Clin Rev Allergy Immunol 2002, 23:5-27.
8. Khan T.Z., Wagener J.S., Bost T., Martinez J., Accurso F.J., Riches D.W.H. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995, 151:1075-1082.
9. Armstrong D.S., Grimwood K., Carlin J.B., et al. Lower airway inflammation in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 1997, 156:1197-1204.
10. Meyer K.C., Zimmerman J. Neutrophil mediators, Pseudomonas, and pulmonary dysfunction in cystic fibrosis. J Lab Clin Med 1993, 121:654-661.
11. Ulrich M, Worlitzsch D, Viglio S, et al. Alveolar inflammation in cystic fibrosis. J Cyst Fibros 2010;9:217-227.
12. Worlitzsch D., Tarran R., Ulrich M., et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002, 109:317-325.
13. Koch C., Høiby N. Pathogenesis of cystic fibrosis. Lancet 1993, 341:1065-1069.
14. Tunney M.M., Field T.R., Moriarty T.F., et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008, 177:995-1001.
15. Worlitzsch D., Rintelen C., Bohm K., et al. Antibiotic-resistant obligate anaerobes during exacerbations of cystic fibrosis patients. Clin Microbiol Infect 2009, 15:454-460.
16. Costerton J.W. Anaerobic biofilm infections in cystic fibrosis. Mol Cell 2002, 10:699-700.
17. McKenney D., Pouliot K.L., Wang Y., et al. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 1999, 284:1523-1527.
18. Goldstein W., Döring G. Lysosomal enzymes and proteinase inhibitors in the sputum of patients with cystic fibrosis. Am Rev Respir Dis 1986, 134:49-56.
19. Cantin A.M. Cystic fibrosis lung inflammation: early, sustained and severe. Am J Respir Crit Care Med 1995, 151:939-941.
20. Fuchs H.J., Borowitz D.S., Christiansen D.H., et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. New Eng J Med 1994, 331:637-642.
21. Rabin H.R., Butler S.M., Wohl M.E., et al. Epidemiologic study of cystic fibrosis: pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2004, 37:400-406.
22. Eschbach M., Schreiber K., Trunk K., Buer J., Jahn D., Schobert M. Long-term anaerobic survival of the opportunistic pathogen Pseudomonas aeruginosa via pyruvate fermentation. J Bacteriol 2004, 186:4596-4604.
23. Borregaard N., Herlin T. Energy metabolism in human neutrophils during phagocytosis. J Clin Invest 1982, 70:550-557.
24. Sbarra A.J., Karnovsky M.L. The biochemical basis of phagocytosis. I. metabolic changes during the ingestion of particles by polymorphonuclear leukocytes. J Biol Chem 1959, 234:1355-1362.
25. Stover C.K., Pham X.Q., Erwin A.L., et al. Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen. Nature 2000, 406:959-964.
26. Peschel A., Jack R.W., Otto M., et al. Staphylococcus aureus resistance to human defensins and evasion of neutrophil killing via the novel virulence factor MprF is based on modification of membrane lipids with l-lysine. J Exp Med 2001, 193:1067-1076.
27. Vandamme P., Holmes B., Coenye T., et al. Burkholderia cenocepacia sp. nov. - a new twist to an old story. Res Microbiol 2003, 154:91-96.
28. Heijerman H., Westerman E., Conway S., Touw D., Döring G. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J Cyst Fibros 2009, 8:295-315.
29. Mannino D.M., Buist A.S., Petty T.L., Enright P.L., Redd S.C. Chronic obstructive pulmonary disease: lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003, 58:388-393.
30. Zemanick E.T., Harris J.K., Conway S., et al. Measuring and improving respiratory outcomes in cystic fibrosis lung disease: opportunities and challenges to therapy. J Cyst Fibros 2009, 9:1-16.
31. Krilov L.R., Blumer J.L., Stern R.C., Hartstein A.I., Iglewski B.N., Goldmann D.A. Imipenem/cilastatin in acute pulmonary exacerbations of cystic fibrosis. Rev Infect Dis 1985, 7(suppl. 3):S482-S489.
32. Pedersen S.S., Jensen T., Hoiby N., Koch C., Flensborg E.W. Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients. Acta Paediatr Scand 1987, 76:955-961.
33. Smith A.L., Redding G., Doershuk C., et al. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis. J Pediatr 1988, 112:547-554.
34. Berger M. Inflammatory mediators in cystic fibrosis lung disease. Allergy Asthma Proc 2002, 23:19-25.
35. Kolpen M., Hansen C.R., Bjarnsholt T., et al. Polymorphonuclear leukocytes consume oxygen in sputum from chronic Pseudomonas aeruginosa pneumonia in cystic fibrosis. Thorax 2010, 65:57-62.
36. Nikolaizik W.H., Knöpfli B., Leister E., de Boer P., Sievers B., Schöni M.H. The anaerobic threshold in cystic fibrosis: comparison of V-slope method, lactate turn points, and Conconi test. Pediatr Pulmonol 1998, 25:147-153.
37. Coquelle N., Fioravanti E., Weik M., Vellieux F., Madern D. Activity, stability and structural studies of lactate dehydrogenases adapted to extreme thermal environments. J Mol Biol 2007, 374:547-562.